| The duration of non-rodent toxicity studies for pharmaceuticals. International Conference on Harmonication (ICH). | |
| | |
MedLine Citation:
|
PMID: 10416259 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
At the present time, there are no uniform standards for the duration of non-rodent chronic toxicity studies. The European Union (EU) requires a 6-month non-rodent study. In Japan, a 6-month study is sufficient for most, but not all, compounds. The U.S. Food and Drug Administration (FDA) maintains its standard duration of 12 months for non-rodents, with 6-month studies accepted for some clinical indications on a case-by-case basis. To achieve harmonization on the duration of non-rodent toxicity studies, each member regulatory region (EU, U.S., and Japan) of the International Conference on Harmonization (ICH) collected non-rodent studies with significant new toxicological findings that had occurred after 6 months. An ICH expert working group was organized that included representatives from the regulatory authorities of each ICH region, to jointly review all available case studies for the purpose of arriving at a consensus on the best duration time for non-rodent toxicity studies. Eighteen case studies were identified and evaluated (16 original cases plus 2 additional FDA cases); most of the toxicities identified fell into the following categories: (1) toxicities identified at 6 months; (2) toxicities observed at 12 months, which were absent or considered isolated and not noteworthy findings at 6 months; (3) drug-related deaths or morbidity that occurred between 6 and 12 months, with a pattern of toxicity that permitted the interpolation of findings to an intermediate interval between 6 and 12 months; and (4) a shift in the dose response for toxicity with increasing duration of drug exposure. Of the 18 cases evaluated, 11 supported a study-duration of 9-12 months, 4 supported a duration of 12 months, and the 3 remaining cases indicated that a 6-month study would be adequate. The working group concluded that there was sufficient evidence to support a harmonized 9-month duration for non-rodent toxicity studies, which would be applicable for most categories of pharmaceuticals. |
| | |
Authors:
|
J J DeGeorge; L L Meyers; M Takahashi; J F Contrera |
Related Documents
:
|
22439129 - Fibrochondrogenesis, an antenatal and postnatal correlation. 10157899 - The impact of expertise and sufficient information on psychologists' ability to detect ... 22141909 - First report of the taiwan sardinella sardinella hualiensis (clupeiformes: clupeidae) i... 1896409 - Progression of exencephaly to anencephaly in the human fetus--an ultrasound perspective. 23551579 - Benign cephalic histiocytosis: case report and review of the literature. 23122009 - Congenital self-healing reticulohistiocytosis: concern for a poor prognosis. 18990519 - Immunocytochemical examinations of biological traces on expanding bullets (qd-pep). 15020369 - Appearance of a type b duplex appendix on barium enema. 10690669 - Appendix perforation by an intrauterine contraceptive device. |
Publication Detail:
|
Type: Guideline; Journal Article; Review |
Journal Detail:
|
Title: Toxicological sciences : an official journal of the Society of Toxicology Volume: 49 ISSN: 1096-6080 ISO Abbreviation: Toxicol. Sci. Publication Date: 1999 Jun |
Date Detail:
|
Created Date: 1999-10-13 Completed Date: 1999-10-13 Revised Date: 2010-09-17 |
Medline Journal Info:
|
Nlm Unique ID: 9805461 Medline TA: Toxicol Sci Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 143-55 Citation Subset: IM |
Affiliation:
|
FDA Center for Drug Evaluation and Research, Office of Review Management, Rockville, MD 28057, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Drug Evaluation Drug Toxicity Europe International Agencies* International Cooperation Japan Time Factors Toxicity Tests* United States |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acquired immune deficiency syndrome (AIDS) presenting as a nasal septal perforation.
Next Document: Quantitative evaluation of alternative mechanisms of blood and testes disposition of di(2-ethylhexyl...